Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DSG3
REST API REST API
Homo sapiens
DSG3 is differentially expressed in 169 experiments: 129 organism parts: skin, tonsil, ... (127 more);, 93 disease states: normal, prostate carcinoma, ... (91 more);, 50 cell types 259 cell lines 12 compound treatments and 59 other conditions.
Synonyms CDHF6
Orthologs CABZ01055869.1 (Danio rerio)   E1BM91_BOVIN (Bos taurus)   F1NHU4_CHICK (Gallus gallus)   FP236168.1 (Danio rerio)   Dsg3 (Mus musculus)   si:ch73-74h11.1 (Danio rerio)   Dsg3 (Rattus norvegicus)   ENSXETG00000031232 (Xenopus laevis)   DSG3_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, apoptosis, membrane, homophilic cell adhesion, cell junction, cell adhesion, integral to membrane, calcium ion binding, desmosome, cellular component disassembly involved in apoptosis
InterPro Term Cadherin, Cadherin_cytoplasmic-dom, Desmo_cadherin, Desmoglein
UniProt Accession P32926
Search EB-eye ENSG00000134757
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-MEXP-1006, E-GEOD-22639, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, ... (21 experiments)

Factor Value U/D Experiments
MOLT4
2
E-MTAB-62, E-MTAB-37
HCC1143
2
E-MTAB-37, E-MTAB-62
HCC2157
2
E-MTAB-62, E-MTAB-37
HCC38
2
E-MTAB-37, E-MTAB-62
MCF-10A
2
E-TABM-420, E-GEOD-14990
NCIH1838
1
E-MTAB-37
253 more value(s).


Cell type

studied in E-GEOD-19397, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (26 experiments)

Factor Value U/D Experiments
stromal cell
1
2
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998
memory B cell
1
E-MEXP-2360
plasma cell
1
E-MEXP-2360
primary T lymphocytes
1
E-GEOD-13909
macrophage
1
E-GEOD-8286
spermatid
1
E-TABM-130
44 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2466, E-MEXP-2069, E-GEOD-5563, ... (40 experiments)

Factor Value U/D Experiments
normal
5
8
E-GEOD-3524, E-GEOD-23878, E-MEXP-66, E-TABM-276, E-MEXP-2069, ... (13 experiments)
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-MTAB-37
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-6631
lung adenocarcinoma
2
E-MTAB-37, E-MEXP-231
Down syndrome
1
E-GEOD-5390
87 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-3284, E-GEOD-6932, E-GEOD-412, E-GEOD-7216, ... (7 experiments)

Factor Value U/D Experiments
none
1
2
E-GEOD-5824, E-GEOD-412, E-GEOD-7400
control - untreated
2
1
E-GEOD-7216
granulocyte-colony stimulating factor
1
E-GEOD-7400
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
rapamycin
1
E-GEOD-5824
bacterial endotoxin
1
1
E-GEOD-3284
6 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
77
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-1561, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-TABM-321, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-127, E-GEOD-22278, E-GEOD-837

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-16194, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, E-TABM-118, ... (27 experiments)

Infection
studied in E-GEOD-9723

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1657

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-1343

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1422

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-19246

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Processing time: 0.395 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM